MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >

Welcome to the MDS Patient Message Board Post New Thread

Welcome to the MDS Patient Message Board. We hope that you will find this to be a very valuable resource in your journey. We have recently revised the format of our forum to be much more user friendly and pleasing on the eyes. Let us know if you have any problems, or if you have additional suggestions on how we might further improve our site.

IMETELSTAT – Recruitment update

Home forums Patient Message Board IMETELSTAT – Recruitment update

This topic contains 0 replies, has 1 voice, and was last updated by  Keith Mallamo 5 months ago.

Viewing 1 post (of 1 total)
  • Author
  • #44921

    Keith Mallamo

    Since ASH 2018, data on IMETELSTAT was found to be “remarkable” in treatment of MDS and MF. IMETELSTAT has clinical evidence of potential disease-modifying activity in three myeloid malignancies: essential thrombocythemia (ET), myelofibrosis (MF) and myelodysplastic syndromes (MDS)

    Below is a link for possible recruitment:
    Recruitment is underway for a study to evaluate the efficacy and safety of IMETELSTAT in transfusion dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment.

    Best of luck to all and hope this possibly helps!

Viewing 1 post (of 1 total)

Register for an account, or login to post to our message boards. Click here.

You must be logged in to reply to this topic.



Search Forums

Review answers to commonly asked questions or get answers to your questions from an MDS expert